|
Amgen, Inc.
|
One Amgen Center Drive
Thousand Oaks, CA 91320-1789
United States |
| Tel: |
1/805/447-1000 |
| URL: |
http://www.amgen.com/ |
|
| Formerly known as: |
| Alantos Pharmaceuticals Holding, Inc |
 |
| Primary Symbols & Exchanges: |
| AMGN - NASDAQ |
| 4332 - Hong Kong |
|
|
| Primary Industry: |
| Biotechnology |
|
|
SIC Industry Code:
|
|
NAICS Industry Code:
|
|
Thomson Financial Business Description:
| The Group's principal activities are to discover, develop, manufacture and market human therapeutics based on advances in cellular and molecular biology. The Group markets human therapeutic products in the areas of hematology, oncology and inflammation. The Group's key products include Aranesp(R) (darbepoetin alfa), EPOGEN(R) (Epoetin alfa), Neulasta(R) (pegfilgrastim), NEUPOGEN(R) (Filgrastim) and Enbrel(R) (etanercept) stimulate the production of red blood cells, for the treatment of anemia associated with chronic renal failure. Neulasta(R) and NEUPOGEN(R) selectively stimulate the production of neutrophils, one type of white blood cell, for treatment of infection in-patients undergoing myelosuppressive chemotherapy. ENBREL(R) blocks the biologic activity of tumor necrosis factor, which is used for treating patients with active rheumatoid arthritis. On 16-Jul-2007, the Group acquired Alantos Pharmaceutical Holding Inc and on 18-Jul-2007, it acquired Ilypsa Inc. |
|
Alacra Alerts:
 
|
Receive alerts on the latest reports on Amgen, Inc.
Subscribe to Alacra Alerts via RSS and never miss the latest research on your favorite companies. Just click the images above to add the feed directly to your favorite newsreader.
|
|
